PDUFA action date of July 22, 2025, with priority review WOBURN, Mass. , Jan. 21, 2025 (GLOBE NEWSWIRE) -- Replimune Group , Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S.
